Showing 1 - 7 results of 7 for search 'Thomas J. Louie', query time: 0.03s Refine Results
  1. 1
    Clostridium difficile in Clinical Practice: Increasing Rates, More Virulent Organisms and New Therapies on the Horizon

    Clostridium difficile in Clinical Practice: Increasing Rates, More Virulent Organisms and New Therapies on the Horizon by Thomas J Louie

    Published 2006-01-01
    Get full text
    Article
  2. 2
    Intravenous to Oral Stepdown Antibiotic Therapy: Another Cost-Effective Strategy in an Era of Shrinking Health Care Dollars

    Intravenous to Oral Stepdown Antibiotic Therapy: Another Cost-Effective Strategy in an Era of Shrinking Health Care Dollars by Thomas J Louie

    Published 1994-01-01
    Get full text
    Article
  3. 3
    Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes

    Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes by Christine Lee, Thomas J. Louie, Karl Weiss, Louis Valiquette, Marvin Gerson, Wendy Arnott, Sherwood L. Gorbach

    Published 2016-01-01
    Get full text
    Article
  4. 4
    Reduction in Clinical Response to Empiric Antimicrobial Therapy of Febrile Granulocytopenic Patients Receiving TMP/SMX Infection Prophylaxis

    Reduction in Clinical Response to Empiric Antimicrobial Therapy of Febrile Granulocytopenic Patients Receiving TMP/SMX Infection Prophylaxis by Eric J Bow, Joseph L Pater, Thomas J Louie, Ronald Feld, Lionel Mandell, Hugh G Robson, Anthony Chow, Andrew Belch, Lilly Miedzinski, Nancy Paul, Catherine R Elliott, Andrew R Willan

    Published 1992-01-01
    Get full text
    Article
  5. 5
    SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)

    SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI) by Sahil Khanna, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa von Moltke, Mark H. Wilcox

    Published 2022-09-01
    Get full text
    Article
  6. 6
    Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

    Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI by Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators

    Published 2024-06-01
    Get full text
    Article
  7. 7
    Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

    Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI by Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators

    Published 2024-08-01
    Get full text
    Article

Search Tools: